Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Fig. 3

a Two-way sensitivity analysis of sCPDie and sCPDieqd for the NMB in the USA. b Two-way sensitivity analysis of sCPDie and sCPDieqd for the NMB in China. c Two-way sensitivity analysis of tCOPDie and csCOP for the NMB in China. sCPDie: the mortality of compensated cirrhotic patients with progression taking sorafenib in full dose; sCPDieqd: the mortality of compensated cirrhotic patients with progression taking sorafenib in adjusted dose; tCOPDie: the mortality of compensated cirrhotic patients without progression taking sorafenib in full dose; csCOP: the cost of sorafenib for compensated cirrhotic patients without progression taking sorafenib in full dose

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us